Meet us at PCTO Summit 2025

Emerald Clinical’s Oncology experts will be attending PCTO Summit 2025, November 17-18 in Boston.

Book a Meeting with our Team

Meet our Vice President, Scientific and Medical Affairs, and Vice President, Global Head of Oncology at PCTO Summit 2025.

Beyond Partners: Collaborators in your Oncology clinical development programs.

Oncology professionals will be gathering at Precision Clinical Trials Oncology Summit Boston 2025 to address challenges, explore revolutionary methodologies, and share success stories from ongoing and completed clinical trials. Meet with Emerald Clinical Trials’ experienced Oncology esperts who blends scientific integrity with operational intelligence to accelerate your oncology drug development program and help shape the future of cancer care.

Emerald Clinical has conducted over 440 oncology studies enrolling nearly 69,000 patients with 25% of those being Early Phase. Our long-standing relationships with global Oncology KOLs differentiate our collaborations. Their clinical experience combined with Emerald’s operational expertise ensure that your study addresses a real clinical need, is efficiently executed, respects patients, and will transition smoothly through phases and regulatory approvals.

Don’t miss our speaker session at 10:05 AM on November 17 in the main presentation hall.

Our Vice President of Scientific and Medical Affairs, Dr. Claudio Hegenberger, and our Vice President, Global Head Oncology, Luke Gill, will share insights on “Accelerate Clinical Development Plans, Guided by Experts.”

_{Dr. Hegenberger is an MD, specialized in Internal Medicine, with an MBA, an MSc in Pharmaceutical Science, and postgraduate certifications from Georgetown University (International Business), Mount Sinai Hospital (Internal Medicine), and Harvard (Nanobiotechnology). He has 27 years of Pharma industry experience, including Country, Regional, and Global Medical Affairs and Clinical Research roles, having extensive experience in Clinical Operations, CROs’ supervision, Pharmacovigilance, Medical Information, and Safety.}

_{Luke Gill, MSc, MBA, has over 25 years of experience in global clinical development and strategic leadership across the biotech and CRO industries. Based in the UK, Gill’s extensive background includes building and scaling global oncology organizations and leading programs from first-in-human studies through pivotal Phase III trials and regulatory submissions. He drives the expansion of the global oncology portfolio, aiming to position Emerald as a trusted strategic partner for innovative oncology development and advance programs that deliver meaningful impact for patients worldwide.}

We will be participating in the panel discussion at 4:10 PM on November 17 in the main presentation hall.

Our Vice President of Scientific and Medical Affairs, Dr. Claudio Hegenberger (Moderator), and our Vice President, Global Head Oncology, Luke Gill (Panelist), will particpate in “Vendors and Sponsors in Oncology Trials 2025 From Transactional to Strategic Partnerships.”

Book a Meeting with our Team

Why Emerald Clinical?

The Emerald Clinical Oncology Advantage:

Our oncology team has over 20 years of cross-functional industry experience in all study aspects and expertise in:

• Navigating rapidly shifting global regulatory environments
• Strong feasibility studies for better site identification
• Engaging Oncology KOLs for advice leading to faster recruitment and higher retention levels
• Dedicated Early Phase teams and assistance with Australian R&D tax benefits
• Access to qualified sites and patients in 70 countries
• Creating early strategies that lead to faster regulatory approval and commercialization

Contact us to discuss our tailored solutions, and collaborative opportunities for your Oncology drug development program.